世界のインフルエンザワクチン市場動向...市場調査レポートについてご紹介

1. Analyst View
2. Research Methodology
3. Influenza Vaccine – Introduction
4. Global Influenza Vaccine Market Outlook 2020
4.1 Current Market Overview and Future Outlook
4.2 Major Marketed Vaccines
4.2.1 Fluzone/Vaxigrip
4.2.2 FluMist
4.2.3 Fluarix and Flulaval
4.2.4 Anflu
4.2.5 Fluvax/Afluria
4.2.6 Flucelvax and Fluvirin
5. Key Geographical Market
5.1 US
5.2 Europe
5.3 Emerging Markets
5.3.1 China
5.3.2 India
5.4 Rest of the World
5.4.1 Australia
5.4.2 Japan
6. Global Influenza Vaccine Market: Pipeline Analysis
7. Global Influenza Vaccine Market: Pricing Analysis
8. Competitive Assessment
8.1 Sanofi
8.1.1 Business Description
8.1.2 Financial Overview
8.1.3 Influenza Vaccine Business
8.2 GlaxoSmithKline Plc (GSK)
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Influenza Vaccine Business
8.3 CSL Ltd
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Influenza Vaccine Business
8.4 AstraZeneca Plc
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Influenza Vaccine Business
8.5 Sinovac Biotech
8.5.1 Business Overview
8.5.2 Financial Overview
8.5.3 Influenza Vaccine Business
8.6 Serum Institute of India
8.6.1 Business Overview
8.6.2 Influenza Vaccine Business

List of Figures:

Figure 4-1: Global – Production Capacity and Production of Influenza Vaccine (Million Doses), 2009 & 2011
Figure 4-2: Global – Influenza Vaccine Sales (Million Doses), 2014 & 2020
Figure 4-3: Global – Influenza Vaccine Market (Billion US$), 2014-2020
Figure 4-4: Global – Influenza Vaccine Market by Players (%), 2014
Figure 4-5: Global – Fluzone/Vaxigrip Sales (Million US$), 2010-2014
Figure 4-6: Global – FluMist Sales (Million US$), 2010-2014
Figure 4-7: Global – Fluarix and FluLaval Sales (Million US$), 2010-2014
Figure 4-8: Global – Anflu Sales (Million Doses), 2010-2013
Figure 4-9: Global – Anflu Sales (Million Doses), 2010-2013
Figure 4-10: Global – Afluria/Fluvax Sales (Million US$), 2012-2014
Figure 4-11: Global – Flucevax and Fluvirin Sales (Million US$), 2012-2014
Figure 5-1: Global – Influenza Vaccine Market by Region (%), 2014
Figure 5-2: US – Influenza Vaccine Sales (Million Doses), 2009-10 to 2014-15
Figure 5-3: US – Influenza Vaccine Market by Players (%), 2014
Figure 5-4: US – Influenza Vaccine Market (Billion US$), 2014-2020
Figure 5-5: Europe – Influenza Vaccine Market by Players (%), 2014
Figure 5-6: Europe – Influenza Vaccine Market (Million US$), 2014-2020
Figure 5-7: Europe – Seasonal Influenza Vaccination Coverage in Older Age Group by Country (%), 2011-12 & 2012-13
Figure 5-8: Emerging Markets – Influenza Vaccine Market by Players (%), 2014
Figure 5-9: Emerging Markets – Influenza Vaccine Market (Million US$), 2014-2020
Figure 5-10: Rest of the World – Influenza Vaccine Market (Million US$), 2014-2020
Figure 8-1: Sanofi – Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-2: Sanofi Pasteur – Breakup of Vaccine Segment by Type (%), 2014
Figure 8-3: Sanofi Pasteur – Breakup of Total Influenza Vaccine Revenues by Geography (%), 2014
Figure 8-4: GlaxoSmithKline Plc – Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-5: GlaxoSmithKline Plc – Breakup of Vaccine Segment by Type (%), 2014
Figure 8-6: GlaxoSmithKline Plc – Breakup of Total Influenza Vaccine Revenue by Geography (%), 2014
Figure 8-7: CSL Ltd – Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-8: CSL Ltd – Breakup of bioCSL Revenues by Product Type (%), 2014
Figure 8-9: AstraZeneca Plc – Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-10: AstraZeneca Plc – Breakup of Infection Segment by Type (%), 2014
Figure 8-11: AstraZeneca Plc – Breakup of Total Influenza Vaccine Revenues by Geography (%), 2014
Figure 8-12: Sinovac Biotech – Breakup of Vaccine by Type (%), 2013

List of Tables:

Table 5-1: US – Major Influenza Vaccines & Manufacturers (2014-15)
Table 5-2: Percentage of People in the US Who Received Influenza Vaccine (2013-14)
Table 5-3: Number of Pediatric Deaths in US Flu Season (2005-06 to 2014-15)
Table 5-4: US – Seasonal Influenza Vaccination Coverage by Group (%), 2011-12 to 2013-14
Table 5-5: Europe – Major Influenza Vaccines & Manufacturers (2014-15)
Table 5-6: China – Vaccine Classification
Table 5-7: Australia – Major Influenza Vaccines & Manufacturer (2014-15)
Table 6-1: Influenza Vaccine – Pipeline Analysis, 2014
Table 7-1: Major Influenza Vaccines Cost/Dose (US$) for 2015-16 Season
Table 8-1: Sanofi – Key Financials (Million US$), 2012-2014
Table 8-2: Influenza Vaccines Offered by Sanofi Pasteur (2014)
Table 8-3: GlaxoSmithKline Plc – Key Financials (Million US$), 2012-2014
Table 8-4: Influenza Vaccines Offered by GlaxoSmithKline Plc (2014)
Table 8-5: CSL Ltd. – Key Financials (Million US$), 2012-2014
Table 8-6: CSL Influenza Vaccine Portfolio before Merger
Table 8-7: CSL Influenza Vaccine Portfolio after Merger
Table 8-8: AstraZeneca Plc – Key Financials (Million US$), 2012-2014
Table 8-9: Influenza Vaccines Offered by AstraZeneca Plc (2014)
Table 8-10: Sinovac Biotech – Key Financials (Million US$), 2011-2013
Table 8-11: Influenza Vaccines Offered by Sinovac Biotech (2014)